FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2007 Apr 4

PMID 17404812

Citations 8

Authors

Jae Sung Lee

Hajime Orita

Kathleen Gabrielson

Sara Alvey

Ruth L Hagemann

Francis P Kuhajda

Edward Gabrielson

Martin G Pomper

Affiliations

Soon will be listed here.

Abstract

Purpose: Fatty acid synthase (FAS) is an emerging target for anticancer therapy with a variety of new FAS inhibitors being explored in preclinical models. The aim of this study was to use positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) to monitor the effects of the FAS inhibitor C75 on tumor glucose metabolism in a rodent model of human A549 lung cancer.

Materials And Methods: After a baseline FDG-PET scan, C75 was administered and post-treatment scans were performed serially. FAS activity was measured in treated animals ex vivo by [(14)C]acetate incorporation in animals euthanized in parallel to those imaged.

Results: Longitudinally measured metabolic volumes of interest and tumor/background ratios demonstrated a transient, reversible decrease in glucose metabolism and tumor metabolic volume after treatment, with the peak effect seen at 4 h. FDG-PET measurements correlated with changes in tumor FAS activity measured ex vivo.

Conclusions: Because C75 causes an effect that is shorter in duration than expected, modification of the current weekly dosing regimen should be considered. These results demonstrate the utility of small animal FDG-PET in assessing the pharmacodynamics of new anticancer agents in preclinical models.

Citing Articles

Noninvasive cell tracking using molecular imaging: A useful tool for developing mesenchymal stem cell-based cancer treatment.

Rajendran R, Jogalekar M, Gangadaran P, Ahn B World J Stem Cells. 2021; 12(12):1492-1510.

PMID: 33505597 PMC: 7789123. DOI: 10.4252/wjsc.v12.i12.1492.

In Vivo Imaging With Confirmation by Histopathology for Increased Rigor and Reproducibility in Translational Research: A Review of Examples, Options, and Resources.

Gabrielson K, Maronpot R, Monette S, Mlynarczyk C, Ramot Y, Nyska A ILAR J. 2018; 59(1):80-98.

PMID: 30541081 PMC: 6645176. DOI: 10.1093/ilar/ily010.

The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.

Deford-Watts L, Mintz A, Kridel S Curr Pharm Biotechnol. 2013; 14(3):300-12.

PMID: 23597406 PMC: 3837380. DOI: 10.2174/1389201011314030006.

Non-invasive molecular imaging for preclinical cancer therapeutic development.

OFarrell A, Shnyder S, Marston G, Coletta P, Gill J Br J Pharmacol. 2013; 169(4):719-35.

PMID: 23488622 PMC: 3687654. DOI: 10.1111/bph.12155.

Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy.

Sankaranarayanapillai M, Zhang N, Baggerly K, Gelovani J Mol Imaging Biol. 2012; 15(2):136-47.

PMID: 22886728 PMC: 3591534. DOI: 10.1007/s11307-012-0587-6.

References

Kuhajda F, Landree L, Ronnett G . The connections between C75 and obesity drug-target pathways. Trends Pharmacol Sci. 2005; 26(11):541-4. DOI: 10.1016/j.tips.2005.09.002. View

Gabrielson E, Pinn M, Testa J, Kuhajda F . Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001; 7(1):153-7. View

Kuhajda F . Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000; 16(3):202-8. DOI: 10.1016/s0899-9007(99)00266-x. View

Saleem A, Charnley N, Price P . Clinical molecular imaging with positron emission tomography. Eur J Cancer. 2006; 42(12):1720-7. DOI: 10.1016/j.ejca.2006.02.021. View

March T, Belinsky S . Refinement of an orthotopic lung cancer model in the nude rat. Vet Pathol. 2001; 38(5):483-90. DOI: 10.1354/vp.38-5-483. View

Cha S, Hu Z, Chohnan S, Lane M . Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc Natl Acad Sci U S A. 2005; 102(41):14557-62. PMC: 1253598. DOI: 10.1073/pnas.0507300102. View

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y . [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7(4):369-79. PMC: 1501150. DOI: 10.1593/neo.04577. View

Pizer E, Thupari J, Han W, Pinn M, Chrest F, Frehywot G . Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000; 60(2):213-8. View

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

10.

Li J, Gorospe M, Chrest F, Kumaravel T, Evans M, Han W . Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001; 61(4):1493-9. View

11.

Weissleder R . Molecular imaging in cancer. Science. 2006; 312(5777):1168-71. DOI: 10.1126/science.1125949. View

12.

McFadden J, Medghalchi S, Thupari J, Pinn M, Vadlamudi A, Miller K . Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Med Chem. 2005; 48(4):946-61. DOI: 10.1021/jm049389h. View

13.

Sebastiani V, Visca P, Botti C, Santeusanio G, Galati G, Piccini V . Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol. 2004; 92(1):101-5. DOI: 10.1016/j.ygyno.2003.10.027. View

14.

Yao R, Seidel J, Johnson C, Daube-Witherspoon M, Green M, Carson R . Performance characteristics of the 3-D OSEM algorithm in the reconstruction of small animal PET images. Ordered-subsets expectation-maximixation. IEEE Trans Med Imaging. 2000; 19(8):798-804. DOI: 10.1109/42.876305. View

15.

Kuhajda F . Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006; 66(12):5977-80. DOI: 10.1158/0008-5472.CAN-05-4673. View

16.

Lupu R, Menendez J . Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?. Endocrinology. 2006; 147(9):4056-66. DOI: 10.1210/en.2006-0486. View

17.

Weber W . Chaperoning drug development with PET. J Nucl Med. 2006; 47(5):735-7. View

18.

Juweid M, Cheson B . Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507. DOI: 10.1056/NEJMra050276. View